Marinus Pharmaceuticals, Inc.

NasdaqGM:MRNS Voorraadrapport

Marktkapitalisatie: US$18.1m

Marinus Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Marinus Pharmaceuticals is Scott Braunstein, benoemd in Aug2019, heeft een ambtstermijn van 5.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.21M, bestaande uit 20.2% salaris en 79.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.22% van de aandelen van het bedrijf, ter waarde $ 39.06K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4 jaar en 4.6 jaar.

Belangrijke informatie

Scott Braunstein

Algemeen directeur

US$3.2m

Totale compensatie

Percentage CEO-salaris20.2%
Dienstverband CEO5.3yrs
Eigendom CEO0.2%
Management gemiddelde ambtstermijn4yrs
Gemiddelde ambtstermijn bestuur4.6yrs

Recente managementupdates

Recent updates

A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price

Sep 20
A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 16
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

May 11
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%

Apr 16
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 08
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Dec 22
Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

Sep 22
Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

Jun 12
Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

May 16
Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Oct 26
Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

Oct 12
Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

Marinus Pharmaceuticals: Positive News Flow Of Note

Sep 22

Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M

Aug 29

Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Aug 13
Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Marinus Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy

Jul 28

Revisiting Marinus Pharmaceuticals

May 05

Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues

Mar 27
Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Mar 03
Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption

Feb 28

Analyse CEO-vergoeding

Hoe is Scott Braunstein's beloning veranderd ten opzichte van Marinus Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$149m

Mar 31 2024n/an/a

-US$145m

Dec 31 2023US$3mUS$650k

-US$141m

Sep 30 2023n/an/a

-US$134m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$35m

Dec 31 2022US$3mUS$591k

-US$20m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$4mUS$574k

-US$99m

Sep 30 2021n/an/a

-US$88m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$76m

Dec 31 2020US$4mUS$556k

-US$76m

Sep 30 2020n/an/a

-US$74m

Jun 30 2020n/an/a

-US$72m

Mar 31 2020n/an/a

-US$69m

Dec 31 2019US$2mUS$305k

-US$54m

Sep 30 2019n/an/a

-US$49m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$43m

Dec 31 2018US$210kn/a

-US$37m

Compensatie versus markt: De totale vergoeding ($USD 3.21M ) Scott } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 655.65K ).

Compensatie versus inkomsten: De vergoeding van Scott is gestegen terwijl het bedrijf verliesgevend is.

CEO

Scott Braunstein (61 yo)

5.3yrs

Tenure

US$3,214,100

Compensatie

Dr. Scott N. Braunstein, M.D., has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He serves as an Independent Director at Caribou Biosciences, Inc. since June 2021. He...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Scott Braunstein
CEO, President & Chairman5.3yrsUS$3.21m0.22%
$ 39.1k
Steven Pfanstiel
COO, CFO & Treasurer3.6yrsUS$1.44m0.031%
$ 5.7k
Joseph Hulihan
Chief Medical Officer5.1yrsUS$1.37m0.031%
$ 5.6k
Alex Aimetti
Chief Scientific Officerno datageen gegevensgeen gegevens
Sonya Weigle
Senior VP of Investor Relations1.4yrsgeen gegevensgeen gegevens
Martha Manning
Senior VP4.4yrsgeen gegevens0.022%
$ 4.0k
Molly Cameron
Director of Corporate Communications & Investor Relations1.4yrsgeen gegevensgeen gegevens
Kimberly McCormick
Chief Regulatory & Quality Assurance Officerno datageen gegevensgeen gegevens
Christina Shafer
Chief Commercial Officer4yrsgeen gegevens0.034%
$ 6.2k
David Czekai
Chief Chemistryno datageen gegevensgeen gegevens

4.0yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MRNS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Scott Braunstein
CEO, President & Chairman6.2yrsUS$3.21m0.22%
$ 39.1k
Timothy Mayleben
Lead Independent Director15.9yrsUS$202.52k0.025%
$ 4.6k
Elan Ezickson
Independent Director4.9yrsUS$162.52k0.010%
$ 1.8k
Jacqueline A. French
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Seth H. Fischer
Independent Director8.2yrsUS$160.02k0.011%
$ 2.0k
Saraswathy Nochur
Independent Director3.7yrsUS$154.74k0.012%
$ 2.1k
Michael Rogawski
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Charles Austin
Independent Director4.3yrsUS$157.52k0.0096%
$ 1.7k
Christine Silverstein
Independent Director1.8yrsUS$249.21kgeen gegevens
Marvin Johnson
Independent Director1.6yrsUS$304.81k0.0044%
$ 787.5
Eugen Trinka
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Elia M. Knight
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens

4.6yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MRNS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).